Studies have shown that CCL-3 and CCL-4 are predominant factors responsible for the enhancement of bone resorption in multiple myeloma [36] and play a causal role in the development of lytic bone lesions in vivo. The gene discussed is CCL4; the disease is plasma cell myeloma.